{
    "nctId": "NCT01724450",
    "briefTitle": "Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity",
    "officialTitle": "Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Heart Failure, Cardiotoxicity",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Prevention of systolic dysfunction in patients undergoing chemotherapy with anthracycline. Systolic dysfunction is characterized by a 10% drop in ejection fraction of left ventricle.",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPatients diagnosed with breast cancer, with an indication of chemotherapy that includes anthracycline.\n\nExclusion Criteria:\n\nFailure analysis of ventricular function; History of chemotherapy or radiotherapy; Previous symptoms of heart failure; Presence of cardiomyopathy; Presence of Coronary Artery Disease; Aortic valve disease or moderate to severe mitral regurgitation; Contraindication to the use of \u03b2-blocker; Use of inhibitors of angiotensin converting enzyme, angiotensin receptor blockers or \u03b2-blockers.\n\nPatients with HER 2 expression",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}